Stella Pharma Corporation
Stella Pharma Corporation (4888.T) Financial Performance & Income Statement Overview
Review Stella Pharma Corporation (4888.T) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Stella Pharma Corporation (4888.T) Income Statement & Financial Overview
Review Stella Pharma Corporation 4888.T income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $706.97M | $85.00M | $108.00M | $61.60M |
| Cost of Revenue | $91.43M | $12.00M | $14.00M | $18.57M |
| Gross Profit | $615.54M | $73.19M | $94.00M | $43.03M |
| Gross Profit Ratio | $0.87 | $0.86 | $0.87 | $0.70 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $330.77M | $179.00M | $196.00M | $209.93M |
| Operating Expenses | $330.77M | $179.00M | $197.00M | $209.93M |
| Total Costs & Expenses | $422.20M | $191.00M | $211.00M | $228.50M |
| Interest Income | $493000.00 | $0.00 | $351000.00 | $345000.00 |
| Interest Expense | $1.35M | $1.05M | $906000.00 | $777000.00 |
| Depreciation & Amortization | $9.81M | $8.75M | $8.50M | $10.58M |
| EBITDA | $244.77M | -$96.18M | -$93.50M | -$149.70M |
| EBITDA Ratio | $0.35 | -$1.13 | -$0.87 | -$2.43 |
| Operating Income | $284.76M | -$106.00M | -$103.00M | -$166.90M |
| Operating Income Ratio | $0.40 | -$1.25 | -$0.95 | -$2.71 |
| Other Income/Expenses (Net) | -$51.15M | $2.00M | -$3.00M | $5.85M |
| Income Before Tax | $233.62M | -$104.00M | -$106.00M | -$161.05M |
| Income Before Tax Ratio | $0.33 | -$1.22 | -$0.98 | -$2.61 |
| Income Tax Expense | $788000.00 | $1.00M | $729000.00 | $712000.00 |
| Net Income | $232.83M | -$105.00M | -$107.00M | -$161.76M |
| Net Income Ratio | $0.33 | -$1.24 | -$0.99 | -$2.63 |
| EPS | $6.85 | -$3.08 | -$3.16 | -$5.12 |
| Diluted EPS | $6.85 | -$3.08 | -$3.16 | -$5.12 |
| Weighted Avg Shares Outstanding | $34.02M | $34.04M | $33.85M | $31.61M |
| Weighted Avg Shares Outstanding (Diluted) | $34.02M | $34.04M | $33.85M | $31.61M |
Over the last four quarters, Stella Pharma Corporation's revenue moved from $61.60M in Q1 2024 to $706.97M in Q4 2024. Operating income in Q4 2024 was $284.76M, with a strong operating margin of 40%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Stella Pharma Corporation remained robust at $244.77M, reflecting operational efficiency. Net income rose to $232.83M, with an EPS of $6.85. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan